2020 World Conference on Lung Cancer.
05 stycznia 2021Prace polskich autorów zakwalifikowane na 2020 World Conference on Lung Cancer odbywającą się wirtualnie w dniach 28-31 stycznia 2021 r.:
- Błach J.M. i wsp. Survival Analysis of Advanced Lung Cancer Patients Undergoing Personalized Treatment or Chemotherapy in a Real Clinic.
- Cedzyńska M. #ES21.03 - The Specifics of Smoking Cessation for Cancer Patients.
- Chmielowska E.C. i wsp. Can Response to Chemotherapy Be a Surrogate of Response to Immunotherapy in Second and Subsequent Lines- Real World Data.
- Chorostowska-Wynimko J. i wsp. The Monitoring of Mutated EGFR Levels in Liquid Biopsy from Patients on EGFR-TKIs – Early Detection of NSCLC Progression.
- Chorostowska-Wynimko J. i wsp. RNA-Based Gene Alteration and Expression Analysis in Sq-NSCLC with known FGFR1 Amplification and Protein Expression Status.
- Dziedzic R. i wsp. Long-Term Results of Screening-Detected Lung Cancer in the Polish Cohort.
- Gil T. i wsp. The Impact of Emphysema Quantified Radiologically on Prolonged Air Leakage (PAL) for 1 vs 2 Chest Tubes after Lung Resection in NSCLC.
- Grenda A. i wsp. Insight Into Intestinal Microbiome in NSCLC Patients: More Personalized Immunotherapy in the Crosshairs.
- Knetki-Wróblewska M. i wsp. Immunotherapy in Non-Small Cell Lung Cancer with High PD-L1 Expression and Coexistent RET- Fusion: The Description of Two Cases.
- Knetki-Wróblewska M. i wsp. Prediction of Pembrolizumab Efficacy in Non-Small-Cell Lung Cancer (NSCLC) Based on Experience From Expanded Access Program in Poland.
- Krawczyk P. i wsp. Influence of Different Concentrations of Nivolumab on T Cell Activation in Patients with Non-Small Cell Lung Cancer: in Vitro Study.
- Płużanski A. i wsp. Safety and Efficacy of First-Line Dacomitinib in Advanced Non-Small Cell Lung Cancer by EGFR Mutation SUBtype in ARCHER 1050.
- Tysarowski A. i wsp. Identification of Gene Fusions and Mutations in Patients with NSCLC using two Diagnostic Approaches: Rapid qPCR and NGS.
- Tysarowski A. i wsp. Comparison of 3 Different Methods for Determination of EGFR p.Thr790Met mutation in patients with NSCLC.
